Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 2012 March 1; 122(3): 1000–1009.
Published online 2012 February 13. doi:  10.1172/JCI59816
PMCID: PMC3287225

Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice


Leptin action on its receptor (LEPR) stimulates energy expenditure and reduces food intake, thereby lowering body weight. One leptin-sensitive target cell mediating these effects on energy balance is the proopiomelano­cortin (POMC) neuron. Recent evidence suggests that the action of leptin on POMC neurons regulates glucose homeostasis independently of its effects on energy balance. Here, we have dissected the physiological impact of direct leptin action on POMC neurons using a mouse model in which endogenous LEPR expression was prevented by a LoxP-flanked transcription blocker (loxTB), but could be reactivated by Cre recombinase. Mice homozygous for the LeprloxTB allele were obese and exhibited defects characteristic of LEPR deficiency. Reexpression of LEPR only in POMC neurons in the arcuate nucleus of the hypothalamus did not reduce food intake, but partially normalized energy expenditure and modestly reduced body weight. Despite the moderate effects on energy balance and independent of changes in body weight, restoring LEPR in POMC neurons normalized blood glucose and ameliorated hepatic insulin resistance, hyperglucagonemia, and dyslipidemia. Collectively, these results demonstrate that direct leptin action on POMC neurons does not reduce food intake, but is sufficient to normalize glucose and glucagon levels in mice otherwise lacking LEPR.


Leptin is an adipose-derived hormone that acts on its cognate receptors (LEPR) expressed by multiple neuronal groups in distinct areas of the brain (1). The canonical effect of leptin action in the brain is to regulate food intake and energy expenditure and thus body weight (24). In addition, leptin regulates several other physiological processes, including hepatic glucose production, insulin action, and glucagon levels (510). It is still unclear, however, which neurons mediate the varied physiological effects of leptin.

One population of neurons targeted by leptin is proopiomelanocortin (POMC) cells in the arcuate nucleus of the hypothalamus (ARH) and nucleus of the solitary tract (NTS) (2, 3). Leptin action on POMC neurons in the ARH is considered a prototypical site of action in the control of energy balance. This view is partly based on results showing that loss of LEPR in POMC neurons increases body weight (8, 11, 12). Conversely, LEPR reexpression in the ARH (13), overexpression in the ARH (1417), and transgenic expression in POMC neurons (18) lower body weight. Interestingly, these latter studies also show lowered blood glucose, suggesting that leptin-sensitive POMC neurons in the ARH directly modulate metabolism (1318). In the current study, we developed what we believe to be a novel LEPR-null mouse model in which endogenous LEPR expression can be reexpressed in cells that normally express leptin receptors. Here, we reexpress LEPR only in POMC neurons to delineate the physiological effects on energy and metabolic homeostasis.


Development and validation of the Lepr reactivatable mouse model.

Similarly to work in previous studies (1923), a LoxP-flanked transcription-blocking cassette was inserted between exons 16 and 17 of the Lepr gene to generate mice lacking the long (B) isoform (Supplemental Figure 1A; supplemental material available online with this article; doi: 10.1172/JCI59816DS1). As predicted, LeprloxTB/loxTB (LeprloxTB) mice were obese compared with LeprWT/WT (WT) controls and comparable to mice harboring naturally occurring LEPR mutations (e.g. db/db; ref. 24 and data not shown). LeprloxTB mice were also hyperglycemic, similarly to db/db animals (data not shown). As a first test of the utility of this model, we made mice with global reexpression of LEPR (Figure (Figure1B).1B). To do so, male LeprloxTB/WT mice were first bred with female LeprloxTB/WT mice, which express zona pellucida 3-cre (Zp3-cre) (25). The genotypes of resulting progeny were produced at expected Mendelian ratios (data not shown). Restoration of LEPR expression in LeprloxTB × Zp3-cre mice rescued obesity and hyperglycemia to levels comparable to that in WT controls, demonstrating that the cre-reactivated LeprloxTB allele was functional (data not shown).

Figure 1
LEPRs are only reactivated in the ARH in LeprloxTB × POMC-cre mice.

Next, LeprloxTB/WT mice were bred with LeprloxTB/WT × POMC-cre mice (11) to restore expression of the B isoforms of LEPR in POMC neurons. Genotypes of resulting progeny were produced at expected Mendelian ratios. Expression of functional LEPR in POMC neurons was validated based on leptin-stimulated phosphorylation of Stat3 (p-Stat3) immunoreactivity in brains of fasted mice. As expected, leptin increased p-Stat3 in numerous regions of the hypothalamus in WT mice (Figure (Figure1A).1A). In contrast, leptin-induced p-Stat3 immunoreactivity was completely absent in LeprloxTB littermates (Figure (Figure1B).1B). In LeprloxTB × POMC-cre mice, leptin-stimulated p-Stat3 was detectable only in the ARH, indicating reexpression of LEPR in POMC neurons (Figure (Figure1C).1C). Costaining p-Stat3–positive neurons in the ARH of WT and LeprloxTB × POMC-cre mice for β-endorphin indicated that approximately one-third of cells overlapped (Figure (Figure1,1, D and F). There was no overlap between p-Stat3 and β-endorphin in the ARH of LeprloxTB littermates (Figure (Figure11E).

To investigate whether LEPR expression is reactivated in POMC neurons outside the ARH, leptin-stimulated p-Stat3 immunoreactivity was also assessed in the hindbrain. Leptin activated p-Stat3 in the hindbrain of WT mice (Figure (Figure1G).1G). This effect was absent in LeprloxTB and LeprloxTB × POMC-cre mice (Figure (Figure1,1, H and I). In addition, immunohistochemistry was used to label ACTH-producing cells in the pituitary of LEPR-cre × tdTomato mice. These results show that few cells in the pituitary coexpress LEPR and ACTH (Supplemental Figure 2, A–C). Plasma corticosterone levels were also similar in 5-hour–fasted LeprloxTB and LeprloxTB × POMC-cre mice (292 ± 53 and 293 ± 48, respectively). Collectively, these results demonstrate that LeprloxTB × POMC-cre mice only express functional LEPR in POMC neurons in the ARH and that our genetic strategy to reactivate this pathway occurs in a physiological manner.

Leptin action in POMC neurons stimulates energy expenditure, but does not regulate food intake.

To determine whether LEPR reactivation in POMC neurons is sufficient to rescue obesity and hyperphagia characteristic of LEPR-null mice, we assessed body weight/composition and energy balance. As shown in Figure Figure2A,2A, male LeprloxTB and LeprloxTB × POMC-cre littermates were similarly obese from 4–12 weeks. Body weight in male LeprloxTB × POMC-cre mice then diverged after 12 weeks versus LeprloxTB littermates and was approximately 15% lower at 20 weeks (Figure (Figure2A).2A). The magnitude of this effect is noteworthy, as it mirrors weight gain ascribed to deletion of LEPR in POMC neurons in the ARH (11). Decreased fat mass in male LeprloxTB × POMC-cre mice compared with LeprloxTB littermates fully accounted for lowered body weight after 12 weeks (Figure (Figure2B).2B). There were no differences in lean mass between male LeprloxTB mice and LeprloxTB × POMC-cre littermates (Figure (Figure2C).2C). Female LeprloxTB × POMC-cre mice were also comparably obese to LeprloxTB littermates, but this effect did not vary with age (Figure (Figure2D).2D). There were no differences in body weight or composition between WT and LEPRWT/WT × POMC-cre mice, indicating that expression of cre-recombinase in POMC neurons did not independently have an impact on energy balance (Figure (Figure2,2, A–D).

Figure 2
Body weight is modestly reduced only in male LeprloxTB × POMC-cre mice after 12 weeks of age compared with LeprloxTB littermates.

To examine leptin’s impact on energy balance and determine mechanism or mechanisms by which LEPR reactivation in POMC neurons reduces body weight in male mice, we used metabolic cages to measure energy expenditure and food intake. Importantly, this was done in LeprloxTB and LeprloxTB × POMC-cre littermates with similar body weight/composition, which are obese compared with WT controls (Figure (Figure3A).3A). Oxygen consumption and carbon dioxide production expressed relative to total body weight were reduced in LeprloxTB mice compared with WT controls, but were partially restored compared with LeprloxTB × POMC-cre littermates (Figure (Figure3,3, B and C). The respiratory exchange ratio (RER) was lower in LeprloxTB mice than in WT controls, but was increased in LeprloxTB × POMC-cre littermates compared with all groups (Figure (Figure3D).3D). Total activity was reduced in LeprloxTB mice compared with WT controls, but was increased over a 24-hour period and during the dark cycle in LeprloxTB × POMC-cre mice compared with other groups (Figure (Figure3E).3E). In contrast, food consumption was similarly elevated in LeprloxTB and LeprloxTB × POMC-cre mice versus WT controls (Figure (Figure3F).3F). Collectively, these results demonstrate that LEPR direct leptin action in POMC neurons in the ARH regulates energy expenditure, but not food intake.

Figure 3
Selective reactivation of LEPR expression in POMC neurons stimulates increased energy expenditure, but does not affect food intake in mice.

Leptin action in POMC neurons normalizes glucose and glucagon levels and improves hepatic insulin sensitivity.

We next assessed the impact of direct leptin action on POMC neurons on several parameters of glucose homeostasis. As expected, blood glucose in male LeprloxTB mice was elevated versus that in WT controls (Figure (Figure4A).4A). Despite only modest effects on body weight and adiposity, blood glucose in male LeprloxTB × POMC-cre mice was fully normalized to WT levels at all measured time points (Figure (Figure4A).4A). Normalization of blood glucose in male LeprloxTB × POMC-cre mice was evident at 6, 8, and 12 weeks, which was prior to divergence of body weight (Figure (Figure4A4A and Figure Figure2A).2A). This indicates that this effect is independent of changes in body weight or adiposity. Plasma insulin in male LeprloxTB × POMC-cre mice was lowered compared with LeprloxTB littermates at 8 weeks, but this difference was absent at 12 and 20 weeks (Figure (Figure4B).4B). Blood glucose and plasma insulin were also similarly lowered in female LeprloxTB × POMC-cre mice in weight- and body composition–matched littermates (Figure (Figure4,4, C and D). Leptin was similarly elevated in LeprloxTB and LeprloxTB × POMC-cre mice at 12 and 20 weeks compared with levels in WT controls (Figure (Figure4E).4E). There were also no differences in blood glucose, plasma insulin, or plasma leptin between WT and LEPRWT/WT × POMC-cre mice, indicating that expression of Cre-recombinase in POMC neurons did not independently alter these parameters (Figure (Figure4,4, A–E). Collectively, these results demonstrate that LEPR signaling only in POMC neurons in the ARH potently regulates blood glucose levels.

Figure 4
Selective reactivation of LEPR expression in POMC neurons improves hyperglycemia and hyperinsulinemia in mice.

We next explored potential mechanisms underlying the ability of leptin action on POMC neurons to regulate blood glucose levels. We used tracer dilution and hyperinsulinemic-euglycemic clamp techniques in 4- to 5-hour–fasted, conscious, chronically catheterized 8-week-old male mice to investigate changes in glucose flux and to determine whether and where insulin action is improved by LEPR reexpression in POMC neurons. Body weight–matched cohorts of LeprloxTB and LeprloxTB × POMC-cre littermate mice were used (Figure (Figure5A).5A). Blood glucose levels were clamped at target levels in all mice (Figure (Figure5B).5B). The steady-state glucose infusion rate (GIR) required to clamp blood glucose in LeprloxTB × POMC-cre mice was increased 150% compared with LeprloxTB littermates, indicating improved whole-body insulin sensitivity (Figure (Figure5C).5C). Clamp insulin levels were similar between LeprloxTB and LeprloxTB × POMC-cre mice, indicating that this variable did not contribute to differences in GIR (Figure (Figure5D).5D). Consistent with lowered short-term fasted blood glucose levels in LeprloxTB × POMC-cre mice, basal glucose turnover was reduced versus that in LeprloxTB animals (Figure (Figure5E).5E). During the clamp, insulin-stimulated suppression of endogenous rate of glucose appearance (endoRa) was restored to WT levels in LeprloxTB × POMC-cre mice (Figure (Figure5E).5E). LeprloxTB mice displayed expected defects in hepatic insulin sensitivity (Figure (Figure5E).5E). In contrast to marked improvements in the liver, insulin-stimulated glucose disposal was similarly impaired in both LeprloxTB and LeprloxTB × POMC-cre mice compared with WT controls (Figure (Figure5F).5F). This suggests that reexpression of LEPRs only in POMC neurons improves insulin sensitivity in the liver, but not in other insulin target tissues such as skeletal muscle and adipose tissue.

Figure 5
Selective reactivation of LEPR expression in POMC neurons improves hepatic insulin sensitivity in mice.

We also assessed plasma glucagon levels in all groups of mice. We found that glucagon was elevated in male LeprloxTB mice at 12 and 20 weeks, but fully restored to WT levels in LeprloxTB × POMC-cre littermates (Figure (Figure6A).6A). Plasma glucagon levels were also inappropriately regulated in response to a fasting/refeeding paradigm in LeprloxTB mice. Glucagon was elevated in LeprloxTB mice in the fed, fasted, and carbohydrate-refed condition (Figure (Figure6B).6B). In contrast, plasma glucagon levels in LeprloxTB × POMC-cre mice were lowered to WT control levels in the fed and carbohydrate-refed state (Figure (Figure6B).6B). Plasma insulin levels in carbohydrate-refed LeprloxTB × POMC-cre mice were also reduced compared with those in LeprloxTB animals (Figure (Figure6C).6C). Pancreata were also isolated to determine whether glucagon and/or insulin content differ in LeprloxTB × POMC-cre mice compared with LeprloxTB littermates. We found that pancreatic content of both hormones was similarly elevated above that in WT controls in LeprloxTB × POMC-cre and LeprloxTB littermate mice (Figure (Figure6,6, D and E).

Figure 6
Inappropriate plasma glucagon levels are corrected in LeprloxTB × POMC-cre mice, and this contributes to improvements in hepatic insulin action.

The contribution of normalized plasma glucagon in LeprloxTB × POMC-cre mice to improvements in insulin sensitivity based on GIR (Figure (Figure5C)5C) and suppression of endoRa (Figure (Figure5E)5E) was next examined. To test this, somatostatin was infused at the onset of the clamp to acutely suppress endogenous glucagon and insulin secretion in LeprloxTB × POMC-cre and LeprloxTB littermate mice of similar body weights (41.9 ± 1.2 and 40.8 ± 1.4 g, respectively). Blood glucose was clamped at target levels in both groups (Figure (Figure6F).6F). The GIR required to clamp blood glucose was 113% higher in LeprloxTB × POMC-cre mice than LeprloxTB littermates, indicating higher insulin sensitivity (Figure (Figure6G).6G). Importantly, this occurred despite no differences in glucagon or insulin between the 2 groups during clamp steady-state conditions (Figure (Figure6,6, H and I, respectively). Plasma C-peptide was also lowered in both groups, indicating that somatostatin inhibited endogenous insulin secretion (basal levels were 11.6 ± 1.3 and 10.5 ± 0.6 ng/ml in LeprloxTB and LeprloxTB × POMC-cre mice, respectively, and were lowered to 0.7 ± 0.2 and 0.7 ± 0.1 ng/ml). In agreement with clamp results in Figure Figure5,5, E and F, the clamp-induced rise in insulin was more effective to suppress endoRa in LeprloxTB × POMC-cre mice than LeprloxTB littermates (Figure (Figure6J).6J). Additionally, insulin-stimulated rate of glucose disappearance (Rd) was comparable between groups (Figure (Figure66K).

Since glucose and lipid metabolism in the liver are interconnected and hormone action in the CNS is increasingly appreciated to regulate hepatic lipid metabolism (26, 27), we assessed plasma and hepatic triglycerides (TGs) and cholesterol in 12- and 20-week-old mice. Remarkably, plasma TG and cholesterol in LeprloxTB × POMC-cre mice were fully and partially restored, respectively, to WT control levels at both ages. (Figure (Figure7,7, A and B). Hepatic TG was also lowered in LeprloxTB × POMC-cre mice to WT levels at both ages, but there were no changes in hepatic cholesterol (Figure (Figure7,7, C and D). These data indicate that leptin action on POMC neurons in the ARH improves both the plasma and hepatic lipid profiles.

Figure 7
Selective reactivation of LEPR expression in POMC neurons improves the lipid profile.


In the current study, we tested the physiological impact of LEPR signaling in POMC neurons on energy balance, glucose, and lipid homeostasis. To do so, we generated a mouse model in which LEPRs are reexpressed only in the subset of POMC neurons that endogenously express LEPRs. We found that selective expression of LEPR in POMC neurons in the ARH on an otherwise LEPR-null background is sufficient to normalize blood glucose and plasma glucagon levels. This manipulation also improved hepatic insulin sensitivity as well as the plasma and hepatic lipid profile. Importantly, these effects were not secondary to reductions in body weight, adiposity, or food intake. Our data further reveal that leptin action on POMC neurons only modestly rescues the obesity characteristic of LEPR deficiency. This reduction in body weight was due to increased energy expenditure and not due to suppression of food intake. Interestingly, reductions in body weight and adiposity only occurred in male mice. Female mice did not exhibit any improvements in body weight, thus complementing prior evidence demonstrating sexually dimorphic LEPR-mediated regulation of energy balance via POMC neurons (28).

Previous work has shown that reactivation or overexpression of LEPR in neurons within the ARH lowers blood glucose levels (1317). A caveat regarding these studies is that they were unable to identify specific neurons transducing leptin signals into normal glucose balance. Huo et al. (18) recently addressed this question using cre-dependent reexpression of LEPR in all POMC neurons in a db/db background. These authors found that transgenic expression of LEPR in all POMC neurons reduced body weight via effects on both energy expenditure and food intake and also lowered blood glucose and plasma insulin levels (18). The effects of reducing food intake in this model contrast with our results as well as our prior work in mice lacking LEPR in POMC neurons, where this loss had minimal effects on food intake in chow-fed mice (8, 11, 12). These disparate results are likely due to differences in the mouse models being examined. One possibility is that Huo et al. (18) used a CMV promoter to reexpress LEPR in POMC neurons, which resulted in transgenic overexpression of LEPR. The CMV promoter is also expressed by all POMC neurons that express cre-recombinase. Prior work has shown that cre-recombinase is present in approximately 95% of POMC neurons in the ARH (11), but only approximately 30%–40% express LEPR (29). We suggest that effects on food intake in Huo et al. (18) may be due to expression of LEPR in POMC neurons that do not normally express LEPR. Candidates for this effect are POMC neurons that express insulin or serotonin 2C receptors. Recent studies, for example, identify that serotonin 2C receptors in POMC neurons regulate food intake (21, 22). The current strategy to reactivate the endogenous receptor and in a physiological manner is supported by data showing that approximately 30%–40% of the p-Stat3–positive cells in the ARH coexpress β-endorphin.

Our results also demonstrate that direct leptin action on POMC neurons lowers glucagon levels and improves hepatic insulin sensitivity. Glucagon and insulin are fundamental to the control of glucose homeostasis, and defects in their regulation are hallmarks of type 2 diabetes (30). The current data related to glucagon complement recent work in models of uncontrolled or type 1 diabetes showing that leptin action in the brain improves glucose homeostasis, in part, by reducing levels of glucagon (5, 7, 31). These data also support pharmacological results in contexts of obesity and type 2 diabetes, finding that inhibition of hepatic glucagon action lowers blood glucose independently of any improvement in body weight and/or energy balance (32, 33). The current results using hyperinsulinemic-euglycemic clamps with or without somatostatin suggest that lowered plasma glucagon in LeprloxTB × POMC-cre accounts for some, but not all, of the improved ability of insulin to suppress endogenous glucose production. These data agree with work in rats showing that i.c.v. administration of leptin during a hyperinsulinemic-euglycemic clamp plus somatostatin enhances the ability of insulin to inhibit hepatic glucose production (34, 35). It is unclear whether lowered glucagon explains these prior results ascribed to leptin action in the CNS because glucagon levels were not reported (34, 35). An additional finding from the clamp studies is that reactivation of LEPR only in POMC neurons in the ARH does not have an impact on insulin-stimulated glucose disposal. This is of note because numerous studies have reported that central administration of leptin stimulates insulin-stimulated (36, 37) and non–insulin-stimulated (9, 38, 39) skeletal muscle glucose uptake. It is speculated that unidentified leptin-sensitive neurons outside the ARH are responsible for these effects.

An additional intriguing metabolic consequence of selective reactivation of LEPR on POMC neurons is marked improvements in circulating and hepatic TG and cholesterol levels. These findings are consistent with reports showing that leptin infusion in the brain of ob/ob mice regulates hepatic lipid metabolism, including plasma and liver TG and cholesterol (4045). Our data suggest that leptin action on POMC neurons is one site where this regulation occurs. Moreover, these current data suggest that such effects can occur independently of leptin-mediated weight loss, which is an issue highlighted by others (44). These findings are potentially important because dyslipidemia and fatty liver are components of metabolic syndrome. It is interesting that these improvements persist in 20-week-old male LeprloxTB × POMC-cre mice in which plasma insulin levels are as high as in LEPR-null littermates. This finding suggests that the regulatory impact of direct leptin action on POMC neurons in the ARH to ameliorate plasma dyslipidemia and hepatic TG accumulation is at least partially insulin independent. Lowered TG in the liver of LeprloxTB × POMC-cre mice is also a possible contributor to improved hepatic insulin sensitivity and thus blood glucose levels. Several studies indicate a link between liver lipid content and hepatic insulin resistance (4648). However, other studies conclude that elevated liver fat per se does not impair hepatic insulin sensitivity (49, 50). With these current data, it is important to consider that hepatic TGs are lowered in LeprloxTB × POMC-cre mice versus LeprloxTB littermates, but they are not normalized to WT levels. Additional work is needed to clarify whether LeprloxTB × POMC-cre mice exhibit subtle differences in the type(s) of lipid present in the liver that may affect hepatic insulin sensitivity or whether these differences are unrelated.

It is currently unclear exactly how leptin action in POMC neurons within the ARH provokes these positive effects in contexts of obesity, hyperglycemia, and insulin resistance. We speculate that this pathway includes activation of melanocortin 4 receptor (MC4R; a target of POMC-derived α-MSH) signaling in the sympathetic nervous system (SNS) to regulate pancreas and liver. This notion is partly based on work showing that reactivation of MC4R in the SNS, but not the parasympathetic nervous system (PNS), of an otherwise MC4R-null mouse ameliorates hepatic insulin resistance. Numerous other reports also show that leptin acts in the brain to regulate the SNS (9, 5153). However, other studies show that leptin acts via the PNS to mediate its beneficial effects (6, 36, 54). Additionally, leptin has been also shown to act independently of melanocortin signaling to modulate liver glucose metabolism. This is a complex issue, and additional studies are needed to test these various possibilities. An additional point in the current studies is that the genetic modification occurred prenatally, which may allow for plasticity and developmental compensation. This issue has been highlighted by work finding disparate phenotypes in mice with pre- and postnatal ablation of AgRP neurons (55). Recent studies have also reported that multiple lineages of hypothalamic neurons express POMC, including cells that do not express POMC in adult mice (56). Future studies employing an inducible model of cre-recombinase in POMC neurons in the LeprloxTB mouse are needed to examine these issues.

In summary, leptin action on POMC neurons in the ARH exerts potent effects to regulate blood glucose levels. Our data also suggest that direct leptin action on POMC neurons does not underlie the ability of leptin to suppress food intake. These results support views that leptin action outside the ARH is needed to induce dramatic weight loss (57). In contrast, our results do not support the conventional model in which leptin acts on POMC in the ARH to simultaneously stimulate energy expenditure and suppress food intake (2, 3). Instead, our data support a modified model of direct leptin action on POMC neurons in the ARH to exert potent effects to regulate numerous facets of glucose homeostasis, including hepatic glucose production. These findings also add to recent literature that suggests leptin may have therapeutic potential in models of type 1 and type 2 diabetes mellitus.


Animal development and care.

To generate LeprloxTB mice, E. coli clones hosting BAC-containing mouse Lepr sequences were obtained from BACPAC (BACPAC Resources Children’s Hospital Oakland, California, USA). BAC DNA clone number RP23-31K16 (containing C57BL/6J mouse strain LEPR sequences) was employed to transform EL350 bacteria (58, 59). loxP sequences in the backbone of the BAC plasmid were removed by homologous recombination as previously described (58, 59). Previously used and validated loxP-flanked transcriptional blocking sequences (23) were amplified by PCR using the following primers: 5′-CATGGGGAACAGATGCATTCCATCATGGCAATGGACCAATGATCCTCAGAGGGCTCCAGGGACACCAATTCGCGCCTAGTCGACTTCGAATAACTT-3′ and 5′-GTGTGATACCCCCCAGAATCATGAGGGAACTCAAGACCATCTATCAAATCAGACACCTCGGAGCTTTCTGGGTGGCGGCCGCTTAGTTTA-3′. They were then cloned between exons 16 and 17 of the LEPR gene by homologous recombination in EL350 (58). EL350 clones hosting correctly engineered Lepr BAC DNA were identified by PCR using the following primers: 5′-CAGGACATCCTGGACAGTATGCTC-3′ and 5′-CAGATGTAGCTAAAAGGCCTATCACAAACT-3′. Sequencing of these amplicons confirmed on-target homologous recombination, absence of mutations in the loxP-flanked transcriptional blocking sequences, and any loss of Lepr native sequences. The genetically engineered Lepr BAC DNA–targeting vector was prepared using a commercially available kit (QIAGEN). Linearized targeting vectors were electroporated into 129X1/SvJ ES cells by standard techniques at the University of Texas Southwestern Medical Center transgenic core facility. The length of homologous arms in the BAC-targeting vector precluded the use of radioactive-based Southern blot and/or long PCR assays to discriminate between ES clones hosting WT and loxP-modified Lepr allele. Thus, an alternative approach consisting of custom multiplex TaqMan quantitative PCR (q-PCR) analyses was devised. In this assay, we employed the commercially available MC4R assay ID Mm00457483_s1 (FAM dye-labeled probe; Applied Biosystems). This assay was used as an endogenous reference. To screen for the loxP-modified Lepr native allele, custom primers (5′-GGCAATGGACCAATGATCCT-3′ and 5′-GACACCTCGGAGCTTTCTGAA-3′) and VIC dye–labeled probe (5′-AGGGCTCCAGGGACA-3′) from Biosearch Technologies (Novato) were multiplexed with the MC4R assay. DNA from ES cell clones able to survive antibiotic selection was extracted as follows: ES cell medium was removed, 250 μl of extraction solution (10 mM tris[hydroxymethyl]aminomethane, 25 mM ethylenediaminetetraacetic acid, 0.5% sodium dodecyl sulfate, 100 mM NaCl, proteinase K 1 mg/ml, pH = 8) was added, and cells were incubated for 4 hours at 55°C. Lysates were then transferred into new tubes containing 125 μl of 5 M NaCl. Tubes were then vigorously shaken, then spun at 21,000 g for 10 minutes at room temperature. Supernatants were then transferred to a new tube, and an amount of 100% ethanol equal to double their volumes was added to it. Tubes were then spun at 21,000 g for 10 minutes at room temperature. Ethanol was then removed and DNA dissolved in distilled water. DNA was then used as template (5–100 ng) in each of the assays (primers and probes were used at 300 and 200 nM [final concentration], respectively). All assays were cycled in an Applied Biosystems PRISM 7900HT sequence detection system. We calculated the difference between the CT values of the custom and the reference q-PCRs; this was the ΔCT. Then we calculated the average WT ΔCT. Individual ΔΔCT values were calculated by subtracting the average WT ΔCT from the individual ΔCT. ES cell clones for which ΔΔCT values were above 0.5 were deemed to be targeted. Mice were subsequently backcrossed on a C57BL/6J background for 2–3 generations. All mice were provided free access to standard chow and water and maintained on a 12-hour light/12-hour dark cycle.


Previously described techniques were used to visualize p-Stat3, β-endorphin, and/or ACTH immunoreactivity as well as the fluorescent reporter tdTomato in the brain or pituitary (1). Mice were fasted 24 hours and injected i.p. with leptin (5 mg/kg; Sigma-Aldrich). Mice were anesthetized 2 hours later using an i.p. injection of chloral hydrate (350 mg/kg) and then perfused transcardially with DEPC-treated 0.9% saline followed by 10% neutral buffered formalin.

Indirect calorimetry.

Energy balance was assessed using TSE Metabolic Cages in the University of Texas Southwestern Mouse Phenotyping Core. Mice were acclimated for 4 days, and measurements were taken during the subsequent 4 days.

Hyperinsulinemic-euglycemic clamp.

Surgical and experimental procedures were previously described (8, 60, 61). Briefly, 8- to 9-week-old mice were transferred to a sterile shoe-box–size cage lined with bedding at 9:00 am to begin a 4- to 5-hour fast. At t = –90 minutes, water was removed, and the first mouse was administered a primed, continuous infusion of [3-3H]glucose (5 μCi bolus + 0.05 μCi/min). Subsequent experiments were begun at 15-minute intervals. At t = –15 and –5 minutes, blood samples from the cut tail were taken to measure insulin, glucose turnover, and 4- to 5-hour–fasted blood glucose. Glucose readings were performed using a glucometer designed for use on rodent samples. At t = 0 minutes, a continuous infusion of insulin (10 mU/kg/min; Humulin) was initiated to raise plasma insulin levels, and the infusion of [3-3H]glucose was increased to 0.1 μCi/min to account for changes in specific activity. In the second cohort of mice, the insulin dose was increased to 25 mU/kg/min, and somatostatin (9 μg/kg/min) was coinfused at t = 0 minutes. In all experiments, blood samples were taken every 10 minutes thereafter to measure blood glucose. A variable GIR (50% dextrose) was used to maintain blood glucose at 150 mg/dl. Blood samples were taken every 10 minutes during the steady-state period (t = 80–120 minutes) to determine clamp hormone levels, endoRa, and Rd.

Fast/refeeding experiments.

Blood samples were taken from the cut tail at 7:30 am after a 12-hour fast to measure insulin and glucagon. One week later, food was removed again at 7:30 pm to initiate a 12-hour fast. The following morning at 7:30 am, mice were fed a carbohydrate diet; blood samples to measure fasted insulin and glucagon were taken 2 hours later.

Hormone measurements.

Insulin was measured using a commercial ELISA kit in the University of Texas Southwestern Mouse Phenotyping Core. Glucagon and corticosterone were measured in the Vanderbilt University Mouse Metabolic Phenotyping Center Hormone Assay Core (Nashville, Tennessee, USA).

Pancreatic insulin and glucagon content.

Pancreata were dissected from anesthetized animals, weighed, and quickly frozen in liquid nitrogen. Pancreata were then homogenized in ice-cold acid ethanol and stored overnight at 4°C. Homogenates were spun in a centrifuge the following morning, and resulting supernatants were stored at –20°C. This process was repeated twice using the remaining pellet. Supernatants were combined and warmed to 37°C; insulin and glucagon were measured using commercial radioimmunoassay kits (Millipore).


Statistical comparisons were made using 1-way ANOVA followed by the Fisher’s least significant difference test for post-hoc comparisons or t tests where appropriate. Data are presented as mean ± SEM. Statistical significance was defined as P < 0.05.

Study approval.

The University of Texas Southwestern IACUC committee approved all procedures.

Supplementary Material

Supplemental data:


The authors would like to thank the staff of the University of Texas Southwestern Mouse Phenotyping Center for assistance. The University of Texas Southwestern Mouse Phenotyping Center is supported by NIH grants PL1 DK081182 and UL1 RR024923. This work was supported by grant 5TL1DK081181 (to E.D. Berglund) and by R01DK53301 and RL1DK081185 (to J.K. Elmquist).


Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2012;122(3):1000–1009. doi:10.1172/JCI59816.


1. Scott MM, et al. Leptin targets in the mouse brain. J Comp Neurol. 2009;514(5):518–532. [PMC free article] [PubMed]
2. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999;22(2):221–232. doi: 10.1016/S0896-6273(00)81084-3. [PubMed] [Cross Ref]
3. Schwartz MW, Woods SC, Porte D, Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000;404(6778):661–671. [PubMed]
4. Flier JS, Maratos-Flier E. Lasker lauds leptin. Cell. 2010;143(1):9–12. doi: 10.1016/j.cell.2010.09.021. [PubMed] [Cross Ref]
5. Fujikawa T, Chuang JC, Sakata I, Ramadori G, Coppari R. Leptin therapy improves insulin-deficient type 1 diabetes by CNS-dependent mechanisms in mice. Proc Natl Acad Sci U S A. 2010;107(40):17391–17396. doi: 10.1073/pnas.1008025107. [PubMed] [Cross Ref]
6. German J, et al. Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve. Endocrinology. 2009;150(10):4502–4511. doi: 10.1210/en.2009-0445. [PubMed] [Cross Ref]
7. German JP, et al. Leptin activates a novel CNS mechanism for insulin-independent normalization of severe diabetic hyperglycemia. Endocrinology. 2011;152(2):394–404. [PubMed]
8. Hill JW, et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab. 2010;11(4):286–297. [PMC free article] [PubMed]
9. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature. 1997;389(6649):374–377. [PubMed]
10. Pocai A, Morgan K, Buettner C, Gutierrez-Juarez R, Obici S, Rossetti L. Central leptin acutely reverses diet-induced hepatic insulin resistance. Diabetes. 2005;54(11):3182–3189. [PubMed]
11. Balthasar N, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron. 2004;42(6):983–991. [PubMed]
12. Shi H, Strader AD, Sorrell JE, Chambers JB, Woods SC, Seeley RJ. Sexually different actions of leptin in proopiomelanocortin neurons to regulate glucose homeostasis. Am J Physiol Endocrinol Metab. 2008;294(3):E630–E639. doi: 10.1152/ajpendo.00704.2007. [PubMed] [Cross Ref]
13. Coppari R, et al. The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 2005;1(1):63–72. doi: 10.1016/j.cmet.2004.12.004. [PubMed] [Cross Ref]
14. Morton GJ, et al. Leptin action in the forebrain regulates the hindbrain response to satiety signals. J Clin Invest. 2005;115(3):703–710. [PMC free article] [PubMed]
15. Morton GJ, et al. Arcuate nucleus-specific leptin receptor gene therapy attenuates the obesity phenotype of Koletsky (fa(k)/fa(k)) rats. Endocrinology. 2003;144(5):2016–2024. [PubMed]
16. Zhang Y, et al. Pro-opiomelanocortin gene transfer to the nucleus of the solitary track but not arcuate nucleus ameliorates chronic diet-induced obesity. NeuroScience. 2010;169(4):1662–1671. [PMC free article] [PubMed]
17. Zhang Y, et al. Simultaneous POMC gene transfer to hypothalamus and brainstem increases physical activity, lipolysis and reduces adult-onset obesity. Eur J Neurosci. 2011;33(8):1541–1550. doi: 10.1111/j.1460-9568.2011.07633.x. [PMC free article] [PubMed] [Cross Ref]
18. Huo L, et al. Leptin-dependent control of glucose balance and locomotor activity by POMC neurons. Cell Metab. 2009;9(6):537–547. doi: 10.1016/j.cmet.2009.05.003. [PMC free article] [PubMed] [Cross Ref]
19. Balthasar N, et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell. 2005;123(3):493–505. doi: 10.1016/j.cell.2005.08.035. [PubMed] [Cross Ref]
20. Rossi J, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011;13(2):195–204. doi: 10.1016/j.cmet.2011.01.010. [PMC free article] [PubMed] [Cross Ref]
21. Xu Y, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. Nat Neurosci. 2010;13(12):1457–1459. [PMC free article] [PubMed]
22. Xu Y, et al. 5-HT2CRs expressed by pro-opiomelanocortin neurons regulate energy homeostasis. Neuron. 2008;60(4):582–589. [PMC free article] [PubMed]
23. Zigman JM, et al. Mice lacking ghrelin receptors resist the development of diet-induced obesity. . J Clin Invest. 2005;115(12):3564–3572. doi: 10.1172/JCI26002. [PMC free article] [PubMed] [Cross Ref]
24. Tartaglia LA. The leptin receptor. J Biol Chem. 1997;272(10):6093–6096. [PubMed]
25. de Vries WN, et al. Expression of Cre recombinase in mouse oocytes: a means to study maternal effect genes. Genesis. 2000;26(2):110–112. doi: 10.1002/(SICI)1526-968X(200002)26:2<110::AID-GENE2>3.0.CO;2-8. [PubMed] [Cross Ref]
26. Perez-Tilve D, et al. Melanocortin signaling in the CNS directly regulates circulating cholesterol. Nat Neurosci. 2010;13(7):877–882. [PMC free article] [PubMed]
27. Nogueiras R, et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest. 2007;117(11):3475–3488. doi: 10.1172/JCI31743. [PMC free article] [PubMed] [Cross Ref]
28. Shi H, Sorrell JE, Clegg DJ, Woods SC, Seeley RJ. The roles of leptin receptors on POMC neurons in the regulation of sex-specific energy homeostasis. Physiol Behav. 2010;100(2):165–172. doi: 10.1016/j.physbeh.2010.02.018. [PubMed] [Cross Ref]
29. Williams KW, et al. Segregation of acute leptin and insulin effects in distinct populations of arcuate proopiomelanocortin neurons. J Neurosci. 2010;30(7):2472–2479. [PMC free article] [PubMed]
30. Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab. 2009;296(1):E11–E21. doi: 10.1152/ajpendo.90563.2008. [PubMed] [Cross Ref]
31. Wang MY, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci U S A. 2010;107(11):4813–4819. doi: 10.1073/pnas.0909422107. [PubMed] [Cross Ref]
32. Liang Y, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes. 2004;53(2):410–417. doi: 10.2337/diabetes.53.2.410. [PubMed] [Cross Ref]
33. Sloop KW, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest. 2004;113(11):1571–1581. [PMC free article] [PubMed]
34. Liu L, et al. Intracerebroventricular leptin regulates hepatic but not peripheral glucose fluxes. J Biol Chem. 1998;273(47):31160–31167. doi: 10.1074/jbc.273.47.31160. [PubMed] [Cross Ref]
35. Rossetti L, et al. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem. 1997;272(44):27758–27763. doi: 10.1074/jbc.272.44.27758. [PubMed] [Cross Ref]
36. Li X, Wu X, Camacho R, Schwartz GJ, LeRoith D. Intracerebroventricular leptin infusion improves glucose homeostasis in lean type 2 diabetic MKR mice via hepatic vagal and non-vagal mechanisms. PLoS One. 2011;6(2):e17058. doi: 10.1371/journal.pone.0017058. [PMC free article] [PubMed] [Cross Ref]
37. Shi ZQ, Nelson A, Whitcomb L, Wang J, Cohen AM. Intracerebroventricular administration of leptin markedly enhances insulin sensitivity and systemic glucose utilization in conscious rats. Metabolism. 1998;47(10):1274–1280. doi: 10.1016/S0026-0495(98)90336-5. [PubMed] [Cross Ref]
38. Minokoshi Y, Haque MS, Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes. 1999;48(2):287–291. doi: 10.2337/diabetes.48.2.287. [PubMed] [Cross Ref]
39. Babic T, Purpera MN, Banfield BW, Berthoud HR, Morrison CD. Innervation of skeletal muscle by leptin receptor-containing neurons. Brain Res. 2010;1345:146–155. doi: 10.1016/j.brainres.2010.05.042. [PMC free article] [PubMed] [Cross Ref]
40. Silver DL, Jiang XC, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob mice. Possible role of leptin in stimulation of HDL turnover. J Biol Chem. 1999;274(7):4140–4146. doi: 10.1074/jbc.274.7.4140. [PubMed] [Cross Ref]
41. Silver DL, Wang N, Tall AR. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest. 2000;105(2):151–159. [PMC free article] [PubMed]
42. Wiegman CH, et al. Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin. Diabetes. 2003;52(5):1081–1089. [PubMed]
43. Donahoo WT, Stob NR, Ammon S, Levin N, Eckel RH. Leptin increases skeletal muscle lipoprotein lipase and postprandial lipid metabolism in mice. Metabolism. 2011;60(3):438–443. doi: 10.1016/j.metabol.2010.03.016. [PubMed] [Cross Ref]
44. Prieur X, Tung YC, Griffin JL, Farooqi IS, O’Rahilly S, Coll AP. Leptin regulates peripheral lipid metabolism primarily through central effects on food intake. Endocrinology. 2008;149(11):5432–5439. [PMC free article] [PubMed]
45. Sharma A, et al. Hepatic gene expression profiling reveals key pathways involved in leptin-mediated weight loss in ob/ob mice. PLoS One. 2010;5(8):e12147. [PMC free article] [PubMed]
46. Samuel VT, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279(31):32345–32353. doi: 10.1074/jbc.M313478200. [PubMed] [Cross Ref]
47. Seppala-Lindroos A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87(7):3023–3028. doi: 10.1210/jc.87.7.3023. [PubMed] [Cross Ref]
48. Marchesini G, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–455. [PubMed]
49. Schonfeld G, Yue P, Lin X, Chen Z. Fatty liver and insulin resistance: not always linked. Trans Am Clin Climatol Assoc. 2008;119:217–223. [PubMed]
50. Raubenheimer PJ, Nyirenda MJ, Walker BR. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes. 2006;55(7):2015–2020. doi: 10.2337/db06-0097. [PubMed] [Cross Ref]
51. Harlan SM, et al. Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circ Res. 2011;108(7):808–812. [PMC free article] [PubMed]
52. Park S, Ahn IS, Kim da S. Central infusion of leptin improves insulin resistance and suppresses beta-cell function, but not beta-cell mass, primarily through the sympathetic nervous system in a type 2 diabetic rat model. Life Sci. 2010;86(23–24):854–862. doi: 10.1016/j.lfs.2010.03.021. [PubMed] [Cross Ref]
53. Haque MS, Minokoshi Y, Hamai M, Iwai M, Horiuchi M, Shimazu T. Role of the sympathetic nervous system and insulin in enhancing glucose uptake in peripheral tissues after intrahypothalamic injection of leptin in rats. Diabetes. 1999;48(9):1706–1712. [PubMed]
54. Pocai A, Obici S, Schwartz GJ, Rossetti L. A brain-liver circuit regulates glucose homeostasis. Cell Metab. 2005;1(1):53–61. [PubMed]
55. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science. 2005;310(5748):683–685. doi: 10.1126/science.1115524. [PubMed] [Cross Ref]
56. Padilla SL, Carmody JS, Zeltser LM. Pomc-expressing progenitors give rise to antagonistic neuronal populations in hypothalamic feeding circuits. Nat Med. 2010;16(4):403–405. [PMC free article] [PubMed]
57. Myers MG, Jr, Munzberg H, Leinninger GM, Leshan RL. The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 2009;9(2):117–123. [PMC free article] [PubMed]
58. Lee EC, et al. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics. 2001;73(1):56–65. doi: 10.1006/geno.2000.6451. [PubMed] [Cross Ref]
59. Liu P, Jenkins NA, Copeland NG. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 2003;13(3):476–484. doi: 10.1101/gr.749203. [PubMed] [Cross Ref]
60. Berglund ED, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology. 2009;150(9):4084–4093. doi: 10.1210/en.2009-0221. [PubMed] [Cross Ref]
61. Berglund ED, et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes. 2008;57(7):1790–1799. doi: 10.2337/db07-1615. [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation